| Literature DB >> 31739404 |
Anton Saerens1, Manosij Ghosh1, Jelle Verdonck1, Lode Godderis1,2.
Abstract
BACKGROUND: Antimony (Sb) trioxide and antimony trisulfide are "2B: Possibly carcinogenic to humans" and "3: Unclassifiable" according to the International Agency for Research on Cancer (IARC). The U.S. National Toxicology Program (NTP) concluded that antimony trioxide "is reasonably anticipated to be a human carcinogen based on studies in rats and mice". We investigated the cancer hazard of antimony compounds for workers, a population with high exposure to antimony substances.Entities:
Keywords: antimony; cancer; occupational health; risk assessment; systematic review
Mesh:
Substances:
Year: 2019 PMID: 31739404 PMCID: PMC6888331 DOI: 10.3390/ijerph16224474
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Antimony compounds.
| Compound Name | Chemical Formula | CAS-Number |
|---|---|---|
| Trivalent Positive (+III) | ||
| antimony trioxide | Sb2O3 | 1309-64-4 |
| antimony trisulfide | Sb2S3 | 1345-04-6 |
| sodium stibogluconate | C12H20O17Sb2.3Na9H2O | 16037-91-5 |
| antimony potassium tartrate | C8H4K2O12Sb2 | 28300-74-5 |
| antimony trifluoride | SbF3 | 7783-56-4 |
| antimony triiodide | SbI3 | 7790-44-5 |
| antimony acetate | Sb(CH3COO)3 | 6923-52-0 |
| antimony trichloride | SbCl3 | 10025-91-9 |
| Trivalent Negative (−III) | ||
| stibine | SbH3 | 7803-52-3 |
| Elemental (0) | ||
| elemental antimony | Sb | 7440-36-0 |
| Pentavalent Positive (+V) | ||
| antimony pentafluoride | SbF5 | 7783-70-2 |
| antimony pentachloride | SbCl5 | 7647-18-9 |
Study design.
| Review Question: Population, Exposure, Comparison, and Outcome (PECO) ( | |||||
|---|---|---|---|---|---|
| Literature Review | |||||
| Human Toxicology | Animal Toxicology | ||||
| Pubmed | ToxNet | Pubmed | ToxNet | ||
| Development of search terms | Development of search terms | Development of search terms | Development of search terms | ||
| Development of Inclusion/Exclusion criteria | Development of Inclusion/Exclusion criteria | ||||
| Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | ||
| Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | ||
| Articles excluded (no original data) | Articles excluded (no original data) | Articles excluded (no original data) | Articles excluded (no original data) | ||
| Additional search with new search terms | Additional search with new search terms | ||||
| Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | ||||
| Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | ||||
| Articles excluded (no original data) | Articles excluded (no original data) | ||||
| Eliminating duplicate articles | Eliminating duplicate articles | ||||
| Final pool of Human Toxicology studies | Final pool of Animal Toxicology studies | ||||
| Data extraction ( | Data extraction ( | ||||
| Quality and Risk of Bias (ROB) assessment of individual studies ( | Quality and Risk of Bias (ROB) assessment of individual studies ( | ||||
| Human Exposure Evidence Integration and Evidence Level | Animal Exposure Evidence Integration and Evidence Level | ||||
| Mechanistic and other relevant elements | |||||
|
| |||||
|
| |||||
|
| |||||
|
| |||||
Population, Exposure, Comparison, and Outcome (PECO).
|
|
| Workers or occupationally exposed people, including possibly sensitive subgroups |
|
|
| Exposure to antimony and antimony compounds (all substances containing antimony), through all possible exposure routes (dermal, inhalation and oral ingestion): |
| - Elemental antimony; |
| - Trivalent antimony (III) and species: Antimony trioxide, antimony trisulfide, antimony trifluoride, antimony trichloride, antimony tribromide, antimony triiodide, antimony potassium tartrate,… |
| - Pentavalent antimony (V) and species: Antimony pentafluoride, antimony pentachloride,… |
| - Trivalent negative antimony (-III) and species. |
|
|
| Non-exposure or exposure beneath threshold that produces critical effect |
|
|
| Development of any type of premalignant lesion, cancer, or malignancy |
Data extraction human studies.
| Reference | Industry, Occupation, Exposure | Sample Characteristics | Sample Size ( | Time period | Study Type | Dose of Exposure | Duration of Exposure | Findings |
|---|---|---|---|---|---|---|---|---|
| Gerhardsson 1982 [ | Metal smelting and refinery (Sb species not specified) | Cases: deceased men in northern Sweden, and who died during the period 1976- 1978, divided into 3 groups (I: death caused by malignancy, II: death caused by cardiovascular disease III: death from other causes); Controls: age-matched men from a town 50 km from the factory | Cases: 40 (I: 15, II: 17, III: 8); Controls: 11 | Before 1978 (death 1976–1978) | Case-control | Not measured, instead tissue concentrations were measured | Duration of employment, interindividual differences. I: 30,9y +- 7,1; II: 32,5 +- 8,2; III: 28,9 +- 10 | Antimony amounts in lung tissue of deceased workers were significantly higher than in the reference group ( |
| Sweeney 1985 [ | Fur workers (Sb species not specified) | Subjects: pensioned fur dressers, compared to Standardized Mortality Ratios (SMR) in the US and in New York City (NYC) | 168 | Before 1977 | Retrospective occupational cohort | Not measured | No data | SMR’s for gross mortality are 118 and 111 (compared to US and NYC rates). Increased risk of death from all malignancies combined (SMR 184 (US) and 151 (NYC), |
| Wingren 1987 [ | Glassworks (Sb species not specified) | Subjects: glassworks employees. Referents: rural referents (farmers, forestry workers,…) | Subjects: 887; Referents: 4611 | 1950–1982 | Retrospective occupational cohort | Not measured | Duration of employment | OR for total cancer was 1.3 (90% CI 1.02–1.4), OR for lung cancer 1.9 (90% CI 1.1–2.5), OR for stomach cancer was 1.6 (90% CI 1.1–2.0), OR for colon cancer was 1.7 (90% CI 1.04–2.5). OR for cancer were highest in glassblowers. |
| Wingren 1990 [ | Glassworks (Sb species not specified) | Subjects: male art glass workers, compared to expected national and county mortality rates | 625 | 1964–1985 | Retrospective occupational cohort | Not measured | At least one month, average exposure per person 15,6 years; 9151 person years at risk | Compared to national and county death rates, a moderate increase in total cancer deaths was observed (not significant; 26 observed cases vs. 22.3 and 18.9 expected from national and county death rates, respectively). Particularly noted for lung cancer, (6 observed cases vs. 4.2 ( |
| Finkelstein 1991 [ | Steel manufacturing (Sb species not specified) | Subjects: deceased workers at an electric arc steel making operation, compared to expected provincial mortality rates | 335 | Deceased before 1989 | Retrospective occupational cohort | Below 10% of TLV for antimony | Ever worked | Eight of thirty men who had ever worked in the pouring pit area died of lung cancer (PMR=provincial mortality rate 276; |
| Gerhardsson 1993 [ | Metal smelting/refinery (antimony sulfides and oxides) | Cases: deceased male smelter workers. Controls: 15 rural and 10 urban controls. | 85 | Before late 1970’s | Case-control | Not measured | 26 to 32 years | An 11-fold higher concentration of Sb in lungs of smelter workers was seen, not associated with higher incidence of lung cancer (compared to non-lung cancer smelter workers or rural or urban controls). |
| Wingren 1993 [ | Glassworks (Sb species not specified) | Subjects: glassworks employees. Referents: rural referents (farmers, forestry workers,…) | Subjects: 887; Referents: 4611 | 1950–1982 | Retrospective occupational cohort | Qualitatively stratified (none, low or high), not measured | Duration of employment, interindividual differences | OR (with 90% CI) for colon cancer were correlated with exposure: no exposure to antimony 1.4 (0.6–3.3) low exposure 1.8 (0.8–13.8) high exposure 5.0 (2.6–9.6); no excess risk for lung cancer and a decrease in stomach cancer risk were seen (no significance level reported). |
| Jones 1994 [ | Metal smelting/refinery (antimony oxides) | Subjects: antimony workers, compared to expected national and county death rates | 525 | Appr. 1940–1992 (study enrollment and follow-up period); split into two groups (before and after 1961) | Retrospective occupational cohort | Average levels of air contamination: 0,0005–0,11 mg/m3 | At least 3 months | An excess of all neoplasm mortality in antimony workers (69 vs 54.7 expected, |
| Schnorr 1995 [ | Antimony smelting (Sb species not specified) | Antimony smelter workers of predominantly hispanic ancestry, compared to national and ethnic specific death rates | 1014 (Hispanics: 923; white Texans: 91) | 1937–1971 (employment and follow-up period)) | Retrospective occupational cohort | Eight hour TWA for Sb exposure in 1975: mean 0,551 mg/m3 (range 0,110–2,0); in 1976 mean 0,747 mg/m3 (range 0,05–6,2) | At least 3 months, 33,773 person years at risk, of which 6.8 years employment per person on average | Overall cancer mortality (SMR 0.88; 95% CI 0.72–1.06) compared to US white mortality rates was diminished. This was expected among the Hispanic subgroup studied. Standardized Mortality Ratios (SMR) for lung cancer were (95% CI): 0.75 (0.51–1.07) and SMR (90% CI) 1.39 (1.01–1.88) relative to U.S. white male mortality rates and Texas ethnic-specific mortality rates, respectively. An increase with duration of employment was seen. A significant excess in mortality was observed for cancers of the liver, biliary tract, and gall bladder (SMR 3.17; 95% CI 1.27–6.52 and SMR 1.58; 95% CI 0.57–3.44 relative to U.S. white male mortality rates and Texas ethnic-specific mortality rates, respectively). Stomach cancer was elevated, but not significantly (SMR 1.49; 95% CI 0.71–2.74 and SMR 1.24; 95% CI 0.50–2.55 relative to U.S. white male mortality rates and Texas ethnic-specific mortality rates, respectively) |
| Jones 2007 [ | Metal smelting/refinery (Sb species not specified) | Subjects: 1462 male workers at a former tin smelter compared to expected national death rates | 1462 | 1972–1991, with back-extrapolation of expsoures until 1937 | Retrospective occupational cohort | 1972–1991: 0,37 mg/m3 (0,001–2,7); extrapolation of exposure data to 3 different scenarios (A, B, C). scenario A: 0,59 (0,003–3,3); scenario B 0,62 (0,003–3,7); scenario C 0,63 (0,003–4,7) | 35 942 person-years at risk | Weighted gradients (assuming that the resulting excess relative risk of lung cancer declines with time since exposure and attained age) and unweighted gradients were calculated for the relationship between Antimony exposure and lung cancer risk. None of the unweighted gradients were significant (significance level 0.05), whereas all of the calculated weighted gradients were significant: A, Sb weighted: 1.66 (0.56, 3.77 |
Data extraction animal studies.
| Animal Studies - Inhalation | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Reference | Antimony Compound | Study Animal and Sex (M: Male, F: Female) | Sample Size | Dose of Exposure | Duration of Exposure | Examinations Relevant to Cancer Development Assessment | Principal Findings | LOAEL/NOAEL | Notes |
| Watt 1983 [ | Antimony trioxide | CDF rats (only F) | 13, 17 and 18 per exposure group, respectively | 0, 1.6, 4.2 mg/m3 | 1 year/2 years | Unknown, data extracted from NTP report | Scirrhous lung carcinoma significantly increased in highest exposure group ( | LOAEL for potential preneoplastic lung lesions (hyperplasia, fibrosis, grossly mottled lungs): 1.6 mg/m3 TWA and LOAEL for lung carcinoma: 4.2 mg/m3 TWA | * interpretation in NTP 2017, authors didn’t make statement about preneoplastic lesions; calculations of significance based on NTP 2017 |
| Groth 1986 [ | Antimony trioxide | Albino Wistar Han rats (M/F) | 90 per sex per exposure group | 0 and 45 or 46 mg/m3 (range 0-91 mg/m3) | 7 hours/day, 5 days/week during 71–73 weeks with intermediate sacrifice at 6, 9 and 12 months (5 per sex per group) | Full necropsy | No lung neoplasms in male rats. Significant increase in lung neoplasms in exposed female rats: total 19/89 vs. 0/89 ( | LOAEL for lung neoplasms in female rats: 45 mg/m3 TWA | |
| Antimony ore concentrate (principally stibnite, Sb2S3) | Albino Wistar Han rats (M/F) | 90 per sex per exposure group | 0 and 36 or 40 mg/m3 (range 0 -191) | 7 hours/day, 5 days/week during 71–73 weeks with intermediate sacrifice at 6, 9 and 12 months (5 per sex per exposure group) | Full necropsy | No lung neoplasms in male rats. Significant increase in lung neoplasms in exposed female rats vs. non-exposed rats: total 17/89 vs. 0/89 ( | LOAEL for lung neoplasms in female rats: 36 mg/m3 TWA | ||
| Newton 1994 [ | Antimony trioxide | Fischer 344 rats (M/F) | 50 per sex per exposure group | 0, 0.25, 1, 5, and 25 mg/m3 | 6 h/day, 5 d/week for 13 weeks followed by 27 week postexposure period | Twice daily observation, gross post mortem examinations, histopathology of heart and airways | Survival equal. Elevated absolute and relative lung weights in two highest exposure groups. Leukemia (typical finding at this age in this species). Increase in lung lesions related to exposure: chronic interstitial inflammation, interstitial fibrosis, granulomatous inflammation in highest exposure groups, bronchiolar/alveolar hyperplasia, increase in alveolar macrophages (no calculation of significance). | NOAEL for carcinoma 25 mg/m3 | |
| Antimony trioxide | Fischer 344 rats (M/F) | 65 per sex per exposure group | 0, 0.05, 0.5, and 5 mg/m3 | 6 h/day, 5 d/week for 52 weeks followed by 52 week postexposure period | Twice daily observation, gross post mortem examinations, histopathology of heart and airways | Increase in potential* preneoplastic lung lesions related to exposure: chronic interstitial inflammation in highest exposure group ( | NOAEL for carcinoma: 5 mg/m3; LOAEL for potential* preneoplastic lung lesions (increase in macrophages): 0.05 mg/m3 | * interpretation in NTP 2017, authors didn’t make statement about preneoplastic lesions; calculations of significance based on NTP 2017 | |
| NTIS/NTP 2016 [ | Antimony trioxide | Wistar Han Rats (M) | 50 per sex per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 h per day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma or carcinoma: no significant difference; Alveolar/bronchiolar carcinoma: no significant difference; Alveolar/bronchiolar adenoma no significant difference. Significantly increased preneoplastic lesions ( | LOAEL for potential preneoplastic lung lesions (alveolar/bronchiolar epithelium hyperplasia): 3 mg/m3 exposure dose; NOAEL and LOAEL for adrenal medulla 10 and 30 mg/m3 | |
| Wistar Han Rats (F) | 50 per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 hper day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma or carcinoma: no significant difference; Alveolar/bronchiolar carcinoma: no significant difference; Alveolar/bronchiolar adenoma: significant increase in two highest exposure groups ( | LOAEL for potential preneoplastic lung lesions (alveolar/bronchiolar epithelium hyperplasia): 3 mg/m3 exposure dose; NOAEL and LOAEL for adrenal medulla 10 and 30 mg/m3 | |||
| Wistar Han Rats (M/F) | 5 per sex exposure group | 0, 3.75, 7.5, 15, 30, or 60 mg/m3 | 6 h plus T90 (12 minutes) per day, 5 d per week for 12 exposure days during a 16-day period | Full necropsy | Lung weights in 30 and 60 mg exposure group increased ( | NOAEL is 15 mg/m3 and LOAEL is 30 mg/m3 for chronic inflammation with hyperplasia and NOAEL and LOAEL for increased lung weights: 15 and 30 mg/m3 | |||
| Wistar Han Rats (M/F) | 5 per sex per exposure group | 0,3,10, 30 mg/m3 | one year, 5 d per week, 6 h per day | MNPCE, MNNCE, PCE, and DNA Comet Assay | No increases in MNPCE, MNNCE, PCE or DNA damage in lung tissue samples or blood leukocytes were observed in male or female Wistar Han rats following exposure to antimony trioxide for 12 months. | NOAEL for MNPCE, PCE and DNA damage in lung tissue: 30 mg/m3 | MNNCE: micronucleated normochromatic erythrocytes; PCE: immature reticulocytes: sign of bone marrow toxicity | ||
| B6C3F1/N mice (M) | 50 per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 h per day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma and Alveolar/bronchiolar carcinoma significantly increased among all exposure groups ( | LOAEL for lung carcinoma and preneoplastic lesions: 3 mg/m3 | |||
| B6C3F1/N mice (F) | 50 per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 h per day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma and Alveolar/bronchiolar carcinoma significantly increased among all exposure groups ( | LOAEL for lung carcinoma, preneoplastic lung lesions and malignant lymphoma: 3 mg/m3 | |||
| B6C3F1/N mice (M/F) | 5 per sex per exposure group | 0, 3.75, 7.5, 15, 30, or 60 mg/m3 | 6 h plus T90 (12 minutes) per day, 5 d per week for 12 exposure days during a 16-day period. | Full necropsy | Relative lung weights were significantly increased in 60 mg/m3 males ( | LOAEL for increased absolute (M) and relative (F) lung weights; NOAEL is 3.75 mg/m3 | |||
| B6C3F1/N mice (M/F) | 5 per sex per exposure group | 0,3,10, 30 mg/m3 | one year, 5 days per week, 6 hours per day | MNPCE, MNNCE, PCE, and DNA Comet Assay | Significant increases in MNNCE at highest exposure concentration ( | LOAEL (lung DNA damage): 3 mg/m3 | |||
|
| |||||||||
| Reference | Antimony Compound | Study animal and sex (M: male, F: female) | Sample size | Dose of Exposure | Duration of exposure | Examinations relevant to cancer development assessment | Principal findings | LOAEL/NOAEL | Notes |
| Kanisawa 1969 [ | Antimony potassium tartrate (APT) | Swiss albino mice (M/F) of the Charles River Strain (CD-1) | 76 for Antimony exposure and 71 controls | 5 mcg/ml drinking water | Lifetime** | Sections of five tissues and gross tumors | Compared to controls, significant differences in the incidences of spontaneous tumors and malignant tumors did not appear. | NOAEL 5 mcg/mL drinking water | **(50% dead males: 582 days, 90% dead males: 651; 50% dead females: 576 days, 90% dead females: 742 d) |
| Schroeder 1970 [ | Antimony potassium tartrate (APT) | Long-Evans strain rats (M/F) | 51 male and 59 female rats (antimony group) and 52 male and 54 female rats (control group) | 5 ppm in drinking water | Lifetime** | Survival time and development of grossly visible tumors | Survival time reduced in antimony fed rats (on average 106 d less for male and 107 d less for females). No significant difference in macroscopic tumor development | LOAEL for increased mortality: 5 ppm drinking water | ** mean per sex: M 746 days (90% dead: 987 days) and F 797 days (90% dead 992 d) |
| Ainsworth 1991 [ | Antimony trioxide | Microtus agrestis (short tailed field vole) | According to exposure duration: 8, 10, 8, 8 and 12, 8 | 500 mg Sb/kg food; | 30, 40, 50, 60 d and 30+5 recovery, 30+10 recovery | Not explicitly stated | No obvious harmful effects: The appearance of the internal organs of voles receiving the 500 mg Sb/ kg diet was indistinguishable from that of the control voles. Wet and dry weights of the liver, kidney, and lungs of animals receiving the 500 mg Sb /kg diet were not significantly different from those of control animals. | NOAEL 500 mg/kg food dose | |
| Antimony trioxide | Microtus agrestis (short tailed field vole) | 6 per exposure group p | 20000 mg Sb/kg food | 12 d | Not explicitly stated | Animals remained healthy. No histological changes compared to control group voles could be observed in the sections of liver and kidney examined by electron microscopy. | NOAEL 20,000 mg/kg food exposure monodose | ||
| Gurnani 1992 (1)[ | Antimony trioxide | Swiss albino mice (M/F) | 5 per exposure group | 0, 400, 666.67 and 1000 mg/kg body mass | 6, 12, 24 h | Chromosomal abberations: chromatid gaps, chromatid breaks, centric fusions and polyploidy in bone marrow cells | In the acute exposure groups, no clastogenic effects were seen. | NOAEL 1000 mg/kg body weight dose | |
| Antimony trioxide | Swiss albino mice (only M) | 5 per exposure group | 0, 400, 666.67 and 1000 mg/kg body mass | 7, 14 and 21 d | Chromosomal abberations: chromatid gaps, chromatid breaks, centric fusions and polyploidy in bone marrow cells | In the 21d exposure groups, dose dependent chromosomal abberations were seen for both sexes ( | LOAEL for CA: 400 mg/kg body weight | ||
| Gurnani 1992 (2)[ | Antimony trichloride | Swiss albino mice | Unknown | Unknown, several | 6, 12, 24 h | Chromosomal abberations in bone marrow cells | Frequencies of chromosomal aberrations (DNA strand breaks principally) were directly related to the dose used and were significantly higher than the control.*** | Inference not possible based on abstract | *** data extracted from abstract |
| Dieter 1992 [ | Antimony potassium tartrate (APT) | Fischer 344 rats (M/F) | 5 per sex for each dose group | 0, 0.15, 0.30, 0.65, 1.25, and 2.5 mg/mL in drinking water or cumulative daily dose of 0, 16, 28, 59, 94, or 168 mg/kg | 14 d | Clinical signs, clinical pathology of several tissues, hematology tests | No clinical nor histopatholigical signs of APT Toxicity in none of the exposure groups | NOAEL of 168 mg APT/kg body weight | |
| Antimony potassium tartrate (APT) | B6C3F1 mice (M/F) | 5 per sex for each dose group | 0, 0.30, 0.65, 1.25, 2.5, and 5.0 mg/mL or cumulative daily dose of 0, 59, 98, 174, 273, or 407 mg/kg | 14 d | Clinical signs, clinical pathology of several tissues, hematology tests | Effects were only seen in 407 mg/kg group: Clinical signs of toxicity: impaired weight gain, rough haircoat, emaciation, abnormal posture, hypoactivity, and decreased fecal material, consistent with avoidance of the APT-dosed water. Histopathological signs: in forestomach: necrosis, ulceration, inflammation and focal hyperplasia of squamous epithelium; in hepatocytes: centriblobular cytoplasmic vacuolization. | NOAEL of 273 mg APT/kg body weight, LOAEL for stomach squamaous epithelium hyperplasia: 407 mg APT/kg body weight | ||
| Poon 1998 [ | Antimony potassium tartrate (APT) | Sprague–Dawley Crl:CD (SD) rats (M/F) | 95 male and 95 female, divided in groups | groups: control (25), 0.5 ppm (15), 5 ppm (15), 50 ppm (15) and 500 ppm (25) | 90 d | Full Necropsy | No clinical signs of toxicity; A male rat in the highest dose group had a cirrhotic liver and a female rat in the lowest dose group had a nodular, fibrotic, spleen. Persistent dose-dependent histological changes in thyroid gland, perisistent dose dependent histological changes in liver (irreversible after 4 wk recovery period), very mild treatment-related changes in spleen developing predominantly in recovery period; changes in thymus in recovery period; minimal non-dose dependent changes in pituitary gland. | inference not possible based on paper | |
| Elliott 1998 [ | Antimony trioxide | CD-1 mice (M/F) | Not indicated | 5000 mg/kg Antimony Trioxide (single dose) OR 400, 666.67, 1000 mL/kg/day | single dose or 7, 14 and 21 d | Micronucleated Polychromatic Erythrocytes (MNPCE) | No difference in micronucleated polychromatic erythrocytes in both species; significant decrease in polychromatic erythrocytes in female mice for single dose study | NOAEL for MNPCE: 5000 mg/kg monodose or 1000 ml/kg repeated dose LOAEL for decrease in PCE: 5000 mg/kg in single dose | |
| Antimony trioxide | Alderley Park Alpk: APfSD rats (only M) | Not indicated; per animal 2000 polychromatic erythrocytes and 1000 erythrocytes | 3200 or 5000 mg/kg | Single dose | Liver DNA repair assay | No significant differences | NOAEL for liver DNA repair: 1000 ml/kg | ||
| Kirkland 2007 [ | Antimony trioxide | Sprague–Dawley Crl:CD (SD) rats (M/F) | 6 per exposure group per sex | 1000 mg once and 250 or 500 or 1000 mg/kg food/day Sb2O3 and positive control CycloPhosphAmid 20 mg/kg once or vehicle controls | Single dose or 21 d | Micronuclei (MN) and chromosomal abberations (CA) | No clinical signs of toxicity. No difference in mitotic indexes between exposed groups and unexposed groups; chromosomal abberations in Sb2O3 treated groups were low (falling within normal ranges) and not significantly higher than in vehicle controls; Micronucleated polychromatic erythrocytes (MNPCE): % PCE not reduced in Sb2O3 treated groups as compared to vehicle control; MN frequencies in Sb2O3 exposed groups within normal ranges and not significantly different from vehicle control groups | NOAEL for MNPCE and CA: 1000 mg/kg food dose | |
|
| |||||||||
| Reference | Antimony Compound | Study animal and sex (M: male, F: female) | Sample size | Dose of Exposure | Duration of exposure | Examinations relevant to cancer development assessment | Principal findings | LOAEL/NOAEL | |
| NTIS/NTP 2016 [ | Antimony trioxide | B6C3F1/N mice (M/F) | 50 per sex per exposure group | 0,3,10, 30 mg/m3 | Two years, 5 d per week, 6 hper day, with interim sacrifice at 6 and 12 months | Skin histopathology | Significant increase in benign fibrous histiocytoma and fibrous histiocytoma/fibrosarcoma ( | LOAEL for male mice and NOAEL for female mice: 30 mg/m3 | |